Worldwide clinical experience with the first marketed leukotriene receptor antagonist
In November 1996, Zeneca Pharmaceuticals introduced ACCOLATE(R) (zafirlukast), a leukotriene receptor antagonist
or LTRA, which was the first product introduced in the first new class of asthma drugs approved by the Food and Drug Administration in nearly 25 years.
5) Options for the management of these cases are to either increase the dose of ICS or to add in another controller agent, such as a long-acting beta-agonist (LABA), a leukotriene receptor antagonist
(LTRA), or a theophylline.
For these patients, elevated urinary leukotriene levels may predict response to a leukotriene receptor antagonist
Antileukotriene therapy consisted of either the leukotriene receptor antagonist
zafirlukast at 20 mg twice a day or the 5-lipoxygenase inhibitor zileuton at 600 mg four times a day.
Montelukast, the leukotriene receptor antagonist
(LTRA), may prevent recurrence of non-asthmatic wheezing in young children where viruses are involved, (7-9) but the evidence is not yet complete.
ACCOLATE, a leukotriene receptor antagonist
, was the first agent in this new class of drugs cleared for marketing by the US Food and Drug Administration in September 1996.
Major Leukotriene Receptor Antagonist
Producer Facility Locations, Output and Market Share
Add a leukotriene receptor antagonist
to the low-dose inhalation glucocorticosteroids.
NEW YORK -- Patients with chronic urticaria got more relief from combination treatment with the leukotriene receptor antagonist
zafirlukast plus an antihistamine than with an antihistamine alone in a 95-patient study, Dr.
ACCOLATE is the first leukotriene receptor antagonist
, a new class of drugs, to receive FDA clearance.
Szefler and colleagues from the National Heart, Lung, and Blood Institute's (NHLBI's) Childhood Asthma Research and Education (CARE) Network found specific differences in responses to the inhaled corticosteroid, fluticasone, and the leukotriene receptor antagonist
, montelukast, in children with mild-to-moderate persistent asthma.